Debbie Rigby takes a look at the latest in research news
This review explores the factors related to urate-lowering therapies adherence with the overall aim of helping health care providers better understand the barriers to adherence. Adherence rates vary widely, from 20% to 70%, and are possibly among the worst for any medication for chronic disease. Enhanced awareness and understanding of the need to treat-to-target in order to improve patient outcomes is needed among health care professionals.
Therapeutics and Clinical Risk Management 2018:14 793–802.
In a large cohort of older adults in primary care, PPI prescription was associated with greater risk of pneumonia (HR 1.82) in the second year of treatment. Records for 75,050 PPI-treated individuals and 75,050 matched controls (mean age 71 years) were eligible for the primary analyses. The number needed to harm (NNH) was 420 for 12 months. These findings support the need for caution in long-term prescribing of PPIs to older adults.
J Am Geriatr Soc 2018.
RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities
A prospective, longitudinal intervention in 150 Australian RACFs has demonstrated pharmacist involvement in a multi-strategic program reduced inappropriate use of antipsychotics and benzodiazepines. The program comprised a psychotropic medication audit and feedback, staff education, and interdisciplinary case review at baseline and 3 months; with a final audit at 6 months.
Med J Aust || doi: 10.5694/mja17.00857
This review investigates the factors that influence deprescribing of medications in primary care from the perspective of general practitioners and community‐living older adults. Trust plays a complex role, acting as both a barrier and facilitator of deprescribing. Individual knowledge gaps of both GPs and older adults influence practices and attitudes towards deprescribing.
Health Sci Rep. 2018;1–13.